News

On International Women’s Day, we celebrate all women in science and health. The OraSure family of companies, including Diversigen, DNA Genotek, and Novosanis, are proud to include a diverse...

We are pleased to announce that Dr Barbara Guinn from University of Hull UK is the winner of the EACR & Novosanis Grant for Cancer Biomarker Detection in Urine.

Novosanis is offering a research grant in collaboration with EACR to stimulate innovative research in cancer biomarker detection using urine as a sample type. Urine can be collected in an...

Novosanis hosted a virtual booth at Eurogin 2021, an international conference focusing on Human Papillomavirus (HPV). Urine, particularly, first-void urine, has potential to screen for...

What a milestone! 8 years and counting. To celebrate our 8th anniversary, we asked our team members to describe Novosanis and their experience in unique words. Teamwork and Innovation were...

In view of the spread of Covid-19 (coronavirus) in our country and across the world, our topmost priority is the health and safety of all our customers and employees. Our team will be...

Today Novosanis Turns 7! On our 7th anniversary, we are proud to share some key highlights.

It's been a few weeks since we've been back from Eurogin 2019. Read our news item sharing a few highlights of our trip and the conference.

Researchers at The Sciensano Institute in Belgium will be using urine collected through Colli-Pee ® to understand Chlamydia presence in all ages and genders in the Belgium population.

Novosanis has been co-awarded a CASUS grant, which allows to build a next-generation Colli-Pee ® that will be used in a molecular screening solution for cervical cancer.

HPV not only has links to cancer, but also infertility